Personalized Treatment in Thyroid Disorders
NCT03517579 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2025-10-15
Summary
The Collar Therapy Indicator (CoTI) (A device that is placed in collar around the neck resembling a turtle neck sweater collar with a wire and recording box) has been shown in a single small previously published experience to provide data regarding radioiodine exposure that correlates with conventional methods of measuring I-123 and I-131 uptakes after diagnostic dose administration and/or therapy for thyroid disorders. We hypothesize that the device's continuous measurement capability will permit more accurate estimates of radiation exposure to thyroid tissue than conventionally employed methods assessing fractional uptake at one or a few time points. It may also provide information about the extent of variability in the absorbed radiation dose among patients with thyroid cancer and hyperthyroidism. By providing more complete information about individual patient's exposures, it will facilitate more accurate estimation of the administered I-131 dose requirements for control of hyperthyroidism and thyroid remnant ablation while reducing the need for repeated visits to the clinic for dosimetry measurements. The aims of our project include the following: (1)To compare quantitative imaging-derived thyroid time activity curve to that obtained using the CoTI and to determine the extent to which there is variability in radiation dose predicted using conventional methods to that predicted from measurement of the full Time-Activity Curve (TAC).(2) Evaluate the uptake and clearance kinetics across the 5 patients in each category as proof of principle for a potential larger trial to investigate use of this device in optimizing the administered doses of radioactive iodine to achieve therapeutic goals while minimizing risks of comorbidities, such a post-radioiodine hypothyroidism in patients with Graves' disease.(3)Evaluate patient experience, convenience, and discomfort in using the CoTI device with a survey instrument.
Conditions
- Thyroid Cancer
- Graves Disease
Interventions
- DEVICE
-
Cervical Collar Therapy Indicator (COTI)
Study Device; The CoTI has 3 components; * A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions. * A cable that connects the collar unit to the Control Unit * A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet. Two types of collar devices will be used: the lower activity and the medium activity 1. Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131. 2. Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Prasanna Santhanam, MBBS, MD · Johns Hopkins University
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 21 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-11
- Primary Completion
- 2027-10-15
- Completion
- 2027-12-15
Countries
- United States
Study Locations
More Related Trials
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
NCT03841617 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
NCT03009357 ·Status: COMPLETED
-
rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter
NCT00275171 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
NCT05733013 ·Status: RECRUITING
-
Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.
NCT00001730 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
NCT06961084 ·Status: RECRUITING ·Phase: PHASE2
-
Hypothyroidism Treated With Calcitonin
NCT03342001 ·Status: COMPLETED ·Phase: PHASE4
-
Recombinant Human Thyroid Stimulating Hormone for Radioiodine 131I Treatment
NCT06405217 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
NCT02278198 ·Status: COMPLETED ·Phase: PHASE1
-
Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer
NCT01840332 ·Status: COMPLETED ·Phase: NA
-
Evaluating an AI Tool for Detecting Thyrotoxic States
NCT07017907 ·Status: NOT_YET_RECRUITING
-
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT02393690 ·Status: COMPLETED ·Phase: PHASE2
-
Heart Rate Monitoring by Wearable Devices in Graves' Disease
NCT04333342 ·Status: UNKNOWN ·Phase: NA
-
Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer
NCT06362772 ·Status: COMPLETED
-
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
NCT07314255 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Different Doses of 131I in Severe Graves' Hyperthyroidism
NCT01039818 ·Status: COMPLETED ·Phase: PHASE3
-
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
NCT00673010 ·Status: COMPLETED ·Phase: PHASE1
-
Block-replacement Therapy During Radioiodine Therapy
NCT00150124 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
NCT01403324 ·Status: TERMINATED ·Phase: NA
-
Multicenter Study Differentiated Thyroid Carcinoma
NCT00144079 ·Status: COMPLETED ·Phase: PHASE3
-
99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer (DTC) Patients
NCT03065218 ·Status: TERMINATED ·Phase: PHASE4
-
Follow up for Patients With Thyroid Cancer Planed for Radioiodine Scan or Treatment
NCT03624751 ·Status: ACTIVE_NOT_RECRUITING
-
Artificial Intelligence-enable Electrocardiogram for Diagnosis and Outcome in Hyperthyroidism
NCT05675670 ·Status: UNKNOWN ·Phase: NA
-
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
NCT03647358 ·Status: RECRUITING ·Phase: PHASE1
-
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
NCT02773667 ·Status: COMPLETED